171 related articles for article (PubMed ID: 33631119)
21. PARP inhibitors trap PARP2 and alter the mode of recruitment of PARP2 at DNA damage sites.
Lin X; Jiang W; Rudolph J; Lee BJ; Luger K; Zha S
Nucleic Acids Res; 2022 Apr; 50(7):3958-3973. PubMed ID: 35349716
[TBL] [Abstract][Full Text] [Related]
22. Combination of talazoparib and olaparib enhanced the curcumin-mediated apoptosis in oral cancer cells by PARP-1 trapping.
Chatterjee S; Dhal AK; Paul S; Sinha S; Das B; Dash SR; Kundu CN
J Cancer Res Clin Oncol; 2022 Dec; 148(12):3521-3535. PubMed ID: 35962813
[TBL] [Abstract][Full Text] [Related]
23. Olaparib enhances curcumin-mediated apoptosis in oral cancer cells by inducing PARP trapping through modulation of BER and chromatin assembly.
Molla S; Chatterjee S; Sethy C; Sinha S; Kundu CN
DNA Repair (Amst); 2021 Sep; 105():103157. PubMed ID: 34144488
[TBL] [Abstract][Full Text] [Related]
24. Dissecting the molecular determinants of clinical PARP1 inhibitor selectivity for tankyrase1.
Ryan K; Bolaňos B; Smith M; Palde PB; Cuenca PD; VanArsdale TL; Niessen S; Zhang L; Behenna D; Ornelas MA; Tran KT; Kaiser S; Lum L; Stewart A; Gajiwala KS
J Biol Chem; 2021; 296():100251. PubMed ID: 33361107
[TBL] [Abstract][Full Text] [Related]
25. PARP inhibitor BMN-673 induced apoptosis by trapping PARP-1 and inhibiting base excision repair via modulation of pol-β in chromatin of breast cancer cells.
Sethy C; Kundu CN
Toxicol Appl Pharmacol; 2022 Feb; 436():115860. PubMed ID: 34998856
[TBL] [Abstract][Full Text] [Related]
26. Olaparib-Based Photoaffinity Probes for PARP-1 Detection in Living Cells.
Voorneveld J; Florea BI; Bakkum T; Mendowicz RJ; van der Veer MS; Gagestein B; van Kasteren SI; van der Stelt M; Overkleeft HS; Filippov DV
Chembiochem; 2020 Sep; 21(17):2431-2434. PubMed ID: 32282108
[TBL] [Abstract][Full Text] [Related]
27. Rad51 Degradation: Role in Oncolytic Virus-Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma.
Ning J; Wakimoto H; Peters C; Martuza RL; Rabkin SD
J Natl Cancer Inst; 2017 Mar; 109(3):1-13. PubMed ID: 28376211
[TBL] [Abstract][Full Text] [Related]
28. Poly(ADP-Ribose) Polymerase-1 inhibition potentiates cell death and phosphorylation of DNA damage response proteins in oxidative stressed retinal cells.
Martín-Guerrero SM; Casado P; Muñoz-Gámez JA; Carrasco MC; Navascués J; Cuadros MA; López-Giménez JF; Cutillas PR; Martín-Oliva D
Exp Eye Res; 2019 Nov; 188():107790. PubMed ID: 31494107
[TBL] [Abstract][Full Text] [Related]
29. PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemia.
Herriott A; Tudhope SJ; Junge G; Rodrigues N; Patterson MJ; Woodhouse L; Lunec J; Hunter JE; Mulligan EA; Cole M; Allinson LM; Wallis JP; Marshall S; Wang E; Curtin NJ; Willmore E
Oncotarget; 2015 Dec; 6(41):43978-91. PubMed ID: 26539646
[TBL] [Abstract][Full Text] [Related]
30. Downregulation of APE1 potentiates breast cancer cells to olaparib by inhibiting PARP-1 expression.
Ma X; Dang C; Min W; Diao Y; Hui W; Wang X; Dai Z; Wang X; Kang H
Breast Cancer Res Treat; 2019 Jul; 176(1):109-117. PubMed ID: 30989461
[TBL] [Abstract][Full Text] [Related]
31. PARP inhibition restores extrinsic apoptotic sensitivity in glioblastoma.
Karpel-Massler G; Pareja F; Aimé P; Shu C; Chau L; Westhoff MA; Halatsch ME; Crary JF; Canoll P; Siegelin MD
PLoS One; 2014; 9(12):e114583. PubMed ID: 25531448
[TBL] [Abstract][Full Text] [Related]
32. Poly (ADP-ribose) polymerase inhibitors sensitize cancer cells to hypofractionated radiotherapy through altered selection of DNA double-strand break repair pathways.
Seo Y; Tamari K; Takahashi Y; Minami K; Tatekawa S; Isohashi F; Suzuki O; Akino Y; Ogawa K
Int J Radiat Biol; 2022; 98(7):1222-1234. PubMed ID: 34919022
[TBL] [Abstract][Full Text] [Related]
33. Poly (ADP-ribose) polymerase-1 as a promising drug target for neurodegenerative diseases.
Thapa K; Khan H; Sharma U; Grewal AK; Singh TG
Life Sci; 2021 Feb; 267():118975. PubMed ID: 33387580
[TBL] [Abstract][Full Text] [Related]
34. The PARP inhibitor olaparib exerts beneficial effects in mice subjected to cecal ligature and puncture and in cells subjected to oxidative stress without impairing DNA integrity: A potential opportunity for repurposing a clinically used oncological drug for the experimental therapy of sepsis.
Ahmad A; Vieira JC; de Mello AH; de Lima TM; Ariga SK; Barbeiro DF; Barbeiro HV; Szczesny B; Törö G; Druzhyna N; Randi EB; Marcatti M; Toliver-Kinsky T; Kiss A; Liaudet L; Salomao R; Soriano FG; Szabo C
Pharmacol Res; 2019 Jul; 145():104263. PubMed ID: 31071432
[TBL] [Abstract][Full Text] [Related]
35. Elucidating the Therapeutic Utility of Olaparib in Sulfatide-Induced Human Astrocyte Toxicity and Neuroinflammation.
Mekhaeil M; Conroy MJ; Dev KK
J Neuroimmune Pharmacol; 2023 Dec; 18(4):592-609. PubMed ID: 37924373
[TBL] [Abstract][Full Text] [Related]
36. Combination of talaporfin photodynamic therapy and Poly (ADP-Ribose) polymerase (PARP) inhibitor in gastric cancer.
Tanaka M; Sasaki M; Suzuki T; Nishie H; Kataoka H
Biochem Biophys Res Commun; 2021 Feb; 539():1-7. PubMed ID: 33388624
[TBL] [Abstract][Full Text] [Related]
37. Combined poly-ADP ribose polymerase and ataxia-telangiectasia mutated/Rad3-related inhibition targets ataxia-telangiectasia mutated-deficient lung cancer cells.
Jette NR; Radhamani S; Arthur G; Ye R; Goutam S; Bolyos A; Petersen LF; Bose P; Bebb DG; Lees-Miller SP
Br J Cancer; 2019 Oct; 121(7):600-610. PubMed ID: 31481733
[TBL] [Abstract][Full Text] [Related]
38. Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond.
Boussios S; Abson C; Moschetta M; Rassy E; Karathanasi A; Bhat T; Ghumman F; Sheriff M; Pavlidis N
Drugs R D; 2020 Jun; 20(2):55-73. PubMed ID: 32215876
[TBL] [Abstract][Full Text] [Related]
39. The PARP inhibitor, olaparib, depletes the ovarian reserve in mice: implications for fertility preservation.
Winship AL; Griffiths M; Lliberos Requesens C; Sarma U; Phillips KA; Hutt KJ
Hum Reprod; 2020 Aug; 35(8):1864-1874. PubMed ID: 32604417
[TBL] [Abstract][Full Text] [Related]
40. PARP inhibition protects against alcoholic and non-alcoholic steatohepatitis.
Mukhopadhyay P; Horváth B; Rajesh M; Varga ZV; Gariani K; Ryu D; Cao Z; Holovac E; Park O; Zhou Z; Xu MJ; Wang W; Godlewski G; Paloczi J; Nemeth BT; Persidsky Y; Liaudet L; Haskó G; Bai P; Boulares AH; Auwerx J; Gao B; Pacher P
J Hepatol; 2017 Mar; 66(3):589-600. PubMed ID: 27984176
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
